FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 (FSHD1)

Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 (FSHD1) explained in plain language.

Never miss a new study

Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 (FSHD1) trials appear

Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 (FSHD1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Breakthrough drug trial offers hope for rare muscle disease

Disease control Recruiting now

This study is testing an experimental drug called AOC 1020 for people with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 participants will receive either the drug or a placebo via IV infusion every six weeks …

Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 (FSHD1)

Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 (FSHD1)

Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 (FSHD1) trials appear

Breakthrough drug trial offers hope for rare muscle disease